Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

Despite the promising result with FLT3 inhibitors in AML, the emergence of resistance poses a significant challenge, leading to a shorter response duration and inferior survival. This is frequently driven by on-target or parallel prosurvival mutations. The emergence of BCR–ABL1 as a mechanism of pos...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ahmad S. Alotaibi, Musa Yilmaz, Sanam Loghavi, Courtney DiNardo, Gautam Borthakur, Tapan M. Kadia, Beenu Thakral, Naveen Pemmaraju, Ghayas C. Issa, Marina Konopleva, Nicholas J. Short, Keyur Patel, Guilin Tang, Farhad Ravandi, Naval Daver
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2020-10-01
Colecção:	Frontiers in Oncology
Assuntos:	FLT3 BCR-ABL FLT3 inhibitors secondary mutations AML
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2020.588876/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!